This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Arck Systems (C)
Larkin, Ian I.Case HBS-911058-ELeadership and People ManagementThe Arck Systems series of cases describes the dilemmas faced by a senior sales manager in determining a sales compensation plan at an enterprise software company. The existing compensation plan is aggressive and highly rewards "star" performers. The cases track a series of changes the manager makes to the sales compensation plan in response to negative and unintended consequences of the existing system. The cases illustrate the tradeoffs inheren...Starting at €5.74
-
eBay Partner Network (C)
Edelman, Benjamin; Larkin, Ian I.Case HBS-910012-EService and Operations ManagementSupplements the (A) case.Starting at €5.74
-
eBay Partner Network (A), (B), (C), and (D), Teaching Note
Edelman, Benjamin; Larkin, Ian I.Teaching Note HBS-910025-EService and Operations ManagementTeaching Note for 910008, 910009, and 910012.Starting at €0.00
-
Arck Systems (A), (B), (C), (D), (E) and (F), Teaching Note
Larkin, Ian I.Teaching Note HBS-911074-ELeadership and People ManagementTeaching Note for 911056, 911057, 911058, 911059, 911060 and 911073.Starting at €0.00
-
dcs plus: Romanian SaaS Firm Goes International - Teaching Note
Phillip C. NellTeaching Note IVEY-8B20M173-EStrategyTeaching Note for product 9B20M173.Starting at €0.00
-
dcs plus: Romanian SaaS Firm Goes International
Phillip C. NellCase IVEY-9B20M173-EEntrepreneurship, StrategyOn a cold Monday morning in January 2018, the founder and chief executive officer of dcs plus was sitting in a taxi on his way to catch a plane to Dubai, United Arab Emirates. In Dubai, he would be visiting the Middle East subsidiary of his company, a RomStarting at €8.20
-
Pfizer and the Challenges of the Pharmaceutical Industry (A)
Renate Kratochvil; Phillip C. NellCase IVEY-9B19M076-EStrategyIn 2018, President of the United States, Donald Trump, criticized the company Pfizer Inc. (Pfizer) for increasing drug prices—which had been a strategic move by Pfizer in response to industry-wide challenges. This announcement highlighted the complex dynaStarting at €8.20
-
Pfizer and the Challenges of the Pharmaceutical Industry (A) - Teaching Note
Renate Kratochvil; Phillip C. NellTeaching Note IVEY-8B19M076-EStrategyTeaching note for product 9B19M076.Starting at €0.00
-
Pfizer and the Challenges of the Pharmaceutical Industry (B) - Teaching Note
Renate Kratochvil; Phillip C. NellTeaching Note IVEY-8B19M077-EStrategyTeaching Note to accompany product 9B19M077.Starting at €0.00
-
Pfizer and the Challenges of the Pharmaceutical Industry (B)
Renate Kratochvil; Phillip C. NellCase IVEY-9B19M077-EStrategyCase B complements Case A, describing pharmaceutical companies’ strategic responses—such as mega-mergers and acquisitions and specialization—to industry-wide global challenges and highlights strategic decisions by Pfizer’s chief executive officers betweenStarting at €5.74